Therapeutic inhibitors (OTCMKTS: INTI – Get a rating) and MaxCyte (NASDAQ: MXCT – Get a rating) are both small-cap medical companies, but which business is superior? We’ll compare the two companies based on their dividend strength, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares the net margins, return on equity and return on assets of Inhibitor Therapeutics and MaxCyte.
| Net margins | Return on equity | return on assets | |
| Therapeutic inhibitors | N / A | N / A | -309.30% |
| MaxCyte | -41.15% | -7.39% | -6.78% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Inhibitor Therapeutics and MaxCyte, as provided by MarketBeat.com.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| Therapeutic inhibitors | 0 | 0 | 0 | 0 | N / A |
| MaxCyte | 0 | 0 | 5 | 0 | 3.00 |
Valuation and benefits
This table compares the revenue, earnings per share (EPS), and valuation of Inhibitor Therapeutics and MaxCyte.
| Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
| Therapeutic inhibitors | N / A | N / A | -$300,000.00 | N / A | N / A |
| MaxCyte | $33.89 million | 13.69 | -$19.08 million | ($0.17) | -26.88 |
Inhibitor Therapeutics has higher revenue, but lower revenue than MaxCyte.
Institutional and Insider Ownership
65.9% of MaxCyte shares are held by institutional investors. 4.6% of Inhibitor Therapeutics shares are held by insiders. By comparison, 5.1% of MaxCyte’s shares are held by insiders. Strong institutional ownership indicates that large fund managers, endowments, and hedge funds believe a company will outperform the market over the long term.
Summary
MaxCyte beats Inhibitor Therapeutics on 5 out of 8 factors compared between the two stocks.
Inhibitor Therapeutics Company Profile (Get a rating)
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and markets therapeutic products for patients with certain cancers and non-cancerous proliferative disorders in the United States. It engages in the development of therapies for prostate and lung cancer using SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
MaxCyte Company Profile (Get a rating)
MaxCyte, Inc., a global life sciences company, is committed to the discovery, development and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cellular assays; ExPERT GTx, a flow electroporation for large-scale transfection in therapeutic applications; and ExPERT VLx for very high volume cell engineering. The company also provides disposable processing sets (PA) to process and electroporate cells; and AP-supporting accessories, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is based in Gaithersburg, Maryland.
Get news and reviews for Inhibitor Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Inhibitor Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.
